Aligos Therapeutics, Inc. ALGS
We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best‑in‑class drug candidates.
Our pipeline of drug candidates includes pevifoscorvir sodium (previously known as ALG-000184) for chronic HBV infection, ALG‑055009 for MASH and obesity, ALG‑097558 for coronavirus infections, and a portfolio of preclinical programs.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 | $0 | — | — |
| R&D | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M | $79.9M | $44.0M | — |
| SG&A | $20.7M | $22.8M | $30.6M | $26.4M | $28.5M | $17.9M | $10.0M | — |
| Total operating expenses | $90.2M | $93.1M | $103.7M | $111.5M | $132.7M | $97.8M | $54.0M | — |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M | -$97.8M | -$54.0M | — |
| Interest expense | $2.2M | $1.7M | $4.3M | $1.5M | — | — | — | — |
| Pre-tax income | -$23.9M | -$130.9M | -$86.9M | -$95.9M | -$128.2M | -$108.4M | -$52.2M | — |
| Income tax | $314.0K | $331.0K | $795.0K | $106.0K | $143.0K | $161.0K | $85.0K | — |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M | -$108.5M | -$52.3M | — |
| EPS, basic | -2.45 | -20.94 | -34.20 | -2.25 | — | — | — | — |
| EPS, diluted | -2.45 | -20.94 | -34.20 | -2.25 | -3.22 | -10.87 | -26.04 | — |
| Shares, diluted (wtd. avg.) | 9.9M | 6.3M | 2.6M | 42.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.3M | $37.0M | $135.8M | $81.5M | $187.0M | $220.9M | $70.1M | $24.5M |
| Short-term investments | $59.5M | $19.9M | — | $44.5M | $3.9M | $23.1M | $48.1M | — |
| Total current assets | $82.9M | $62.1M | $141.1M | $133.5M | $204.4M | $250.0M | $120.2M | — |
| Property, plant and equipment | $1.9M | $2.4M | $3.3M | $4.8M | $6.2M | $8.0M | $8.5M | — |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M | $265.3M | $146.5M | — |
| Accounts payable | $4.0M | $2.6M | $2.5M | $4.7M | $3.0M | $3.3M | $3.8M | — |
| Total current liabilities | $21.2M | $21.7M | $23.9M | $33.1M | $39.0M | $30.3M | $13.8M | — |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M | $45.3M | $29.3M | — |
| Retained earnings | -$642.2M | -$618.0M | -$486.8M | -$399.1M | -$303.1M | -$174.7M | -$66.2M | — |
| Total equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M | $220.0M | -$64.9M | -$13.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M | -$74.3M | -$46.8M | — |
| Depreciation and amortisation | $930.0K | $1.0M | $1.6M | $2.3M | $3.0M | $2.7M | $1.4M | — |
| Stock-based compensation | $5.0M | $8.5M | $12.7M | $14.7M | $13.5M | $3.0M | $752.0K | — |
| Capital expenditure | — | $130.0K | $19.0K | $943.0K | $892.0K | $2.1M | $2.8M | — |
| Investing cash flow | -$37.8M | -$18.3M | $45.0M | -$26.3M | $3.0M | $32.8M | $6.8M | — |
| Financing cash flow | $101.6M | $355.0K | $88.3M | $164.0K | $78.7M | $192.3M | $85.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-092614.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $6.2M | $3.6M | $2.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$52.3M | -$108.5M | -$128.3M | -$96.0M | -$87.7M | -$131.2M | -$24.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |